Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
2802 participants
Study Classification
OBSERVATIONAL
Study Start Date
2009-05-19
Study Completion Date
2013-08-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Normal fetal growth is a critical component of a healthy pregnancy and the long-term health of the offspring. Pivotal to understanding the dynamics of human fetal growth and to defining normal and abnormal fetal growth is the development of standards for fetal growth. The study's purpose was to establish standards for normal fetal growth and size for gestational age for 4 racial/ethnic groups of pregnant women with the eventual creation of individualized standards for fetal growth and improvements in fetal weight estimation. These data for a contemporary cohort of pregnant women should provide data for clinical management.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The NICHD Fetal Growth Study: Twin Gestations
NCT01369940
Fetal Growth Restriction
Growth Discordancy
COMPLETED
Fetal Growth Evaluation by Three-Dimensional Ultrasound
NCT00340171
Pregnancy
COMPLETED
Antenatal Development Evaluated Prospectively
NCT02478554
Retardation, Fetal Growth
Macrosomia, Fetal
WITHDRAWN
NA
Epigenetic Markers in Growth Restricted Human Pregnancies: a Case-controlled Study
NCT00510380
Fetal Growth Retardation
COMPLETED
Gut Microbiota, SCFAs and Glucolipid Metabolism in Pregnant Women With Abnormal Fetal Size and Their Newborns
NCT04399434
Fetal Growth Restriction
Gut Microbiota
Fetal Macrosomia
+1 more
UNKNOWN
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Summary and aims:
Normal fetal growth is a critical component of a healthy pregnancy and the long-term health of the offspring. Pivotal to understanding the dynamics of human fetal growth and to defining normal and abnormal fetal growth is the development of standards for fetal anthropometric parameters measured longitudinally throughout gestation, which, in turn, can be used to develop interval velocity curves and customized for genetic and physiological factors. We propose to conduct a multi-center prospective observational study (1) to establish a standard for normal fetal growth (velocity) and size for gestational age in the U.S. population; (2) to create an individualized standard for fetal growth potential; and (3) to improve accuracy of fetal weight estimation.
Eligibility:
• Healthy, low-risk pregnant women (both obese and nonobese) between the ages of 18 and 40 from each of the following four self-identified race/ethnicity backgrounds: African American, Asian, Caucasian, and Hispanic.
Design:
* Observational cohort design where pregnant women are recruited prior to 13 weeks gestation and followed throughout pregnancy and delivery for women having livebirths.
* After a sonogram at enrollment (10-13 weeks), women were randomized to receive sonograms according to one of the following four schedules: schedule A: 16, 24, 30, 34, and 38 weeks; schedule B: 18, 26, 31, 35, and 39 weeks; schedule C: 20, 28, 32, 36, and 40 weeks; schedule D: 22, 29, 33, 37, and 41 weeks.
* An enrollment interview was followed by depression screening, physical activity, anthropometric assessment and ultrasonology screening for measurement of fetal growth, and at each of the 5 subsequent visits.
* Uterine artery and fetal Doppler studies at selected gestational weeks.
* Women were asked to provide blood samples at enrollment and at follow-up visits at 16-22 weeks, 24-29 weeks, and 34-37 weeks of gestation.
* Neonatal anthropometry completed for all infants within 12-24 hours after birth.
* Cord blood, plasma, and placenta samples were collected for a smaller subsample of newborns.
* Post-study evaluations: Women who were diagnosed with gestational diabetes during pregnancy were asked to return for a follow-up visit 6 weeks after delivery.
Enrollment:
Final recruitment included 2,802 women with singleton pregnancies of which 2,334 were healthy, low-risk women with pre-pregnancy body mass indices (BMI) between 19-29.9 kg/m2. The racial/ethnic distribution of participating women were: Caucasians (n=614), African American (n=611), Hispanics (n=649), and Asians (n=460), and reflects natality characteristics of contemporary U.S. births. An additional 468 obese women (BMI 30-44.9 kg/m2) were also recruited.
Quality Control:
The quality of the ultrasound measures was guaranteed by implementation of: (1) a comprehensive quality control protocol for ante hoc training and credentialing of all site sonographers, developed by the sonology center at Columbia University, and (2) a rigorous protocol for post hoc quality control, whereby a random sample of all scans, stratified by clinical site and visit, was re-measured for accuracy and reliability.
Normal fetal growth is a critical component of a healthy pregnancy and the long-term health of the offspring. Pivotal to understanding the dynamics of human fetal growth and to defining normal and abnormal fetal growth is the development of standards for fetal anthropometric parameters measured longitudinally throughout gestation, which, in turn, can be used to develop interval velocity curves and customized for genetic and physiological factors. We propose to conduct a multi-center prospective observational study (1) to establish a standard for normal fetal growth (velocity) and size for gestational age in the U.S. population; (2) to create an individualized standard for fetal growth potential; and (3) to improve accuracy of fetal weight estimation.
Eligibility:
• Healthy, low-risk pregnant women (both obese and nonobese) between the ages of 18 and 40 from each of the following four self-identified race/ethnicity backgrounds: African American, Asian, Caucasian, and Hispanic.
Design:
* Observational cohort design where pregnant women are recruited prior to 13 weeks gestation and followed throughout pregnancy and delivery for women having livebirths.
* After a sonogram at enrollment (10-13 weeks), women were randomized to receive sonograms according to one of the following four schedules: schedule A: 16, 24, 30, 34, and 38 weeks; schedule B: 18, 26, 31, 35, and 39 weeks; schedule C: 20, 28, 32, 36, and 40 weeks; schedule D: 22, 29, 33, 37, and 41 weeks.
* An enrollment interview was followed by depression screening, physical activity, anthropometric assessment and ultrasonology screening for measurement of fetal growth, and at each of the 5 subsequent visits.
* Uterine artery and fetal Doppler studies at selected gestational weeks.
* Women were asked to provide blood samples at enrollment and at follow-up visits at 16-22 weeks, 24-29 weeks, and 34-37 weeks of gestation.
* Neonatal anthropometry completed for all infants within 12-24 hours after birth.
* Cord blood, plasma, and placenta samples were collected for a smaller subsample of newborns.
* Post-study evaluations: Women who were diagnosed with gestational diabetes during pregnancy were asked to return for a follow-up visit 6 weeks after delivery.
Enrollment:
Final recruitment included 2,802 women with singleton pregnancies of which 2,334 were healthy, low-risk women with pre-pregnancy body mass indices (BMI) between 19-29.9 kg/m2. The racial/ethnic distribution of participating women were: Caucasians (n=614), African American (n=611), Hispanics (n=649), and Asians (n=460), and reflects natality characteristics of contemporary U.S. births. An additional 468 obese women (BMI 30-44.9 kg/m2) were also recruited.
Quality Control:
The quality of the ultrasound measures was guaranteed by implementation of: (1) a comprehensive quality control protocol for ante hoc training and credentialing of all site sonographers, developed by the sonology center at Columbia University, and (2) a rigorous protocol for post hoc quality control, whereby a random sample of all scans, stratified by clinical site and visit, was re-measured for accuracy and reliability.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Pregnancy
Fetal Growth
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low risk singleton cohort
Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 19.0-29.9 kg/m2 were in the low-risk cohort.
No interventions assigned to this group
Obese cohort
Women with singleton gestations were enrolled between 8w0d and 13w6d and followed up to nine months (2009-2013) in this prospective cohort study. A sub-set of women with and without gestational diabetes were followed up to 6 weeks postpartum. Enrollment was based upon a predefined set of criteria including medical/reproductive history and pre-pregnancy body mass index. Women with a body mass index between 30.0-44.9 kg/m2 were in the obese cohort.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Singleton, viable pregnancy
* 8 plus 0 - 13 plus 6 weeks of gestation
* Maternal age 18 - 40 years
* BMI 19.0 -29.9kg/m(2) for low risk group; BMI 30.0 - 45.0kg/m(2) for obese group
* Firm LMP
* LMP-date and ultrasound date match within 5 days for gestation estimates between 8 weeks + 0 days and 10 weeks + 6 days, 6 days for those between 11 weeks + 0 days and 12 weeks + 6 days, and 7 days for estimates between 13 weeks + 0 days and 13 weeks + 6 days
* No confirmed or suspected fetal congenital structural or chromosomal anomalies
* Expect to deliver at one of the participating hospitals
* No previous participation in the NICHD Fetal Growth Study
* 8 plus 0 - 13 plus 6 weeks of gestation
* Maternal age 18 - 40 years
* BMI 19.0 -29.9kg/m(2) for low risk group; BMI 30.0 - 45.0kg/m(2) for obese group
* Firm LMP
* LMP-date and ultrasound date match within 5 days for gestation estimates between 8 weeks + 0 days and 10 weeks + 6 days, 6 days for those between 11 weeks + 0 days and 12 weeks + 6 days, and 7 days for estimates between 13 weeks + 0 days and 13 weeks + 6 days
* No confirmed or suspected fetal congenital structural or chromosomal anomalies
* Expect to deliver at one of the participating hospitals
* No previous participation in the NICHD Fetal Growth Study
Exclusion Criteria
* Smoked cigarettes or used illicit drugs in the six months
* Used illicit drugs in the past year
* Having at least 1 alcoholic drink per day
* Conception by ovulation stimulation drugs or assisted reproductive technology
* Chronic hypertension or renal disease under medical supervision
* Asthma requiring weekly medication
* Diabetes mellitus
* Thyroid disease under medical supervision
* Autoimmune disorder (rheumatoid arthritis, lupus, antiphospholipid antibody syndrome,scleroderma)
* Hematologic disorders (chronic anemia, sickle cell disease thrombocytopenia coagulation defects, thrombophilia)
* Cancer
* HIV or AIDS
* Epilepsy or seizure on medication or occurrence within 2 years
* Psychiatric disorder (bipolar disorder, depression, anxiety disorder currently requiring medication)
* Current anorexia nervosa or bulimia
* Previous severe preclampsia, eclampsia, HELLP syndrome
* Previous stillbirth or neonatal death
* Previous very preterm birth (less than 34 weeks)
* Previous low birthweight (less than 2,500 g)
* Previous macrosomia (greater than or equal to 4,500 g)
The following criteria apply only to obese women only:
* Chronic hypertension or high blood pressure requiring two or more medications
* Diabetes while not pregnant
* Chronic renal disease under medical supervision
* Autoimmune disease (rheumatoid arthritis, lupus, antiphospholipid antibody syndrome, scleroderma)
* Psychiatric disorder (bipolar disorder, depression, anxiety disorder currently requiring medication)
* Cancer (currently receiving treatment)
* HIV or AIDS
* Used illicit drugs in the past year
* Having at least 1 alcoholic drink per day
* Conception by ovulation stimulation drugs or assisted reproductive technology
* Chronic hypertension or renal disease under medical supervision
* Asthma requiring weekly medication
* Diabetes mellitus
* Thyroid disease under medical supervision
* Autoimmune disorder (rheumatoid arthritis, lupus, antiphospholipid antibody syndrome,scleroderma)
* Hematologic disorders (chronic anemia, sickle cell disease thrombocytopenia coagulation defects, thrombophilia)
* Cancer
* HIV or AIDS
* Epilepsy or seizure on medication or occurrence within 2 years
* Psychiatric disorder (bipolar disorder, depression, anxiety disorder currently requiring medication)
* Current anorexia nervosa or bulimia
* Previous severe preclampsia, eclampsia, HELLP syndrome
* Previous stillbirth or neonatal death
* Previous very preterm birth (less than 34 weeks)
* Previous low birthweight (less than 2,500 g)
* Previous macrosomia (greater than or equal to 4,500 g)
The following criteria apply only to obese women only:
* Chronic hypertension or high blood pressure requiring two or more medications
* Diabetes while not pregnant
* Chronic renal disease under medical supervision
* Autoimmune disease (rheumatoid arthritis, lupus, antiphospholipid antibody syndrome, scleroderma)
* Psychiatric disorder (bipolar disorder, depression, anxiety disorder currently requiring medication)
* Cancer (currently receiving treatment)
* HIV or AIDS
Minimum Eligible Age
18 Years
Maximum Eligible Age
40 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Germaine M Louis, M.D.
Role: PRINCIPAL_INVESTIGATOR
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama
Birmingham, Alabama, United States
Site Status
Fountain Valley Regional Hospital
Fountain Valley, California, United States
Site Status
University of California-Long Beach
Long Beach, California, United States
Site Status
University of California, Irvine Medical Center
Orange, California, United States
Site Status
Christiana Care Health Services
Newark, Delaware, United States
Site Status
Northwestern University
Chicago, Illinois, United States
Site Status
Saint Peters University Hospital
New Brunswick, New Jersey, United States
Site Status
New York Presbyterian Healthcare System
Flushing, New York, United States
Site Status
Columbia University
New York, New York, United States
Site Status
Women and Infants
Providence, Rhode Island, United States
Site Status
Medical University of South Carolina
Charleston, South Carolina, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Zhang C, Hediger ML, Albert PS, Grewal J, Sciscione A, Grobman WA, Wing DA, Newman RB, Wapner R, D'Alton ME, Skupski D, Nageotte MP, Ranzini AC, Owen J, Chien EK, Craigo S, Kim S, Grantz KL, Louis GMB. Association of Maternal Obesity With Longitudinal Ultrasonographic Measures of Fetal Growth: Findings From the NICHD Fetal Growth Studies-Singletons. JAMA Pediatr. 2018 Jan 1;172(1):24-31. doi: 10.1001/jamapediatrics.2017.3785.
Reference Type
BACKGROUND
Grantz KL, Grewal J, Kim S, Grobman WA, Newman RB, Owen J, Sciscione A, Skupski D, Chien EK, Wing DA, Wapner RJ, Ranzini AC, Nageotte MP, Craigo S, Hinkle SN, D'Alton ME, He D, Tekola-Ayele F, Hediger ML, Buck Louis GM, Zhang C, Albert PS. Unified standard for fetal growth: the Eunice Kennedy Shriver National Institute of Child Health and Human Development Fetal Growth Studies. Am J Obstet Gynecol. 2022 Apr;226(4):576-587.e2. doi: 10.1016/j.ajog.2021.12.006. Epub 2021 Dec 11. No abstract available.
Reference Type
BACKGROUND
Grantz KL, Kim S, Grobman WA, Newman R, Owen J, Skupski D, Grewal J, Chien EK, Wing DA, Wapner RJ, Ranzini AC, Nageotte MP, Hinkle SN, Pugh S, Li H, Fuchs K, Hediger M, Buck Louis GM, Albert PS. Fetal growth velocity: the NICHD fetal growth studies. Am J Obstet Gynecol. 2018 Sep;219(3):285.e1-285.e36. doi: 10.1016/j.ajog.2018.05.016. Epub 2018 May 24.
Reference Type
BACKGROUND
Buck Louis GM, Grewal J, Albert PS, Sciscione A, Wing DA, Grobman WA, Newman RB, Wapner R, D'Alton ME, Skupski D, Nageotte MP, Ranzini AC, Owen J, Chien EK, Craigo S, Hediger ML, Kim S, Zhang C, Grantz KL. Racial/ethnic standards for fetal growth: the NICHD Fetal Growth Studies. Am J Obstet Gynecol. 2015 Oct;213(4):449.e1-449.e41. doi: 10.1016/j.ajog.2015.08.032.
Reference Type
RESULT
Hediger ML, Fuchs KM, Grantz KL, Grewal J, Kim S, Gore-Langton RE, Buck Louis GM, D'Alton ME, Albert PS. Ultrasound Quality Assurance for Singletons in the National Institute of Child Health and Human Development Fetal Growth Studies. J Ultrasound Med. 2016 Aug;35(8):1725-33. doi: 10.7863/ultra.15.09087. Epub 2016 Jun 27.
Reference Type
RESULT
Grewal J, Grantz KL, Zhang C, Sciscione A, Wing DA, Grobman WA, Newman RB, Wapner R, D'Alton ME, Skupski D, Nageotte MP, Ranzini AC, Owen J, Chien EK, Craigo S, Albert PS, Kim S, Hediger ML, Buck Louis GM. Cohort Profile: NICHD Fetal Growth Studies-Singletons and Twins. Int J Epidemiol. 2018 Feb 1;47(1):25-25l. doi: 10.1093/ije/dyx161. No abstract available.
Reference Type
RESULT
Guivarch C, Wu J, Lu R, Grewal J, Yu G, Li LJ, Yang J, Pang WW, Wang DD, Weir NL, Chen Z, Tsai MY, Zhang C. Longitudinal plasma amino acids during pregnancy and neonatal anthropometry: findings from the NICHD Fetal Growth Studies-Singleton Cohort. BMC Med. 2025 Jun 9;23(1):343. doi: 10.1186/s12916-025-04146-3.
Reference Type
DERIVED
Le R, Biedrzycki RJ, Tekola-Ayele F. Maternal obesity and ancestry distance in influencing birth outcomes. Int J Obes (Lond). 2025 Aug;49(8):1532-1542. doi: 10.1038/s41366-025-01783-9. Epub 2025 Apr 12.
Reference Type
DERIVED
Wagner KA, Chen Z, Hinkle SN, Gleason JL, Lee W, Grobman WA, Owen J, Newman RB, Skupski DW, He D, Sherman S, Gore-Langton RE, Zhang C, Grewal J, Grantz KL. Relationship between gestational weight gain with fetal body composition and organ volumes in the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Fetal Dimensional Study: a prospective pregnancy cohort. Am J Clin Nutr. 2025 Feb;121(2):367-375. doi: 10.1016/j.ajcnut.2024.12.007. Epub 2025 Jan 16.
Reference Type
DERIVED
Li LJ, Lu R, Rawal S, Birukov A, Weir NL, Tsai MY, Wu J, Chen Z, Zhang C. Maternal plasma phospholipid polyunsaturated fatty acids in early pregnancy and thyroid function throughout pregnancy: a longitudinal study. Am J Clin Nutr. 2024 Apr;119(4):1065-1074. doi: 10.1016/j.ajcnut.2024.02.016. Epub 2024 Feb 24.
Reference Type
DERIVED
Saeed H, Wu J, Tesfaye M, Grantz KL, Tekola-Ayele F. Placental accelerated aging in antenatal depression. Am J Obstet Gynecol MFM. 2024 Jan;6(1):101237. doi: 10.1016/j.ajogmf.2023.101237. Epub 2023 Nov 25.
Reference Type
DERIVED
Mitro SD, Sundaram R, Buck Louis GM, Peddada S, Chen Z, Kannan K, Gleason JL, Zhang C, Grantz KL. Associations of Pregnancy Per- and Polyfluoroalkyl Substance Concentrations and Uterine Fibroid Changes across Pregnancy: NICHD Fetal Growth Studies - Singletons Cohort. Environ Health Perspect. 2023 May;131(5):57007. doi: 10.1289/EHP11606. Epub 2023 May 24.
Reference Type
DERIVED
Grantz KL, Hinkle SN, He D, Owen J, Skupski D, Zhang C, Roy A. A new method for customized fetal growth reference percentiles. PLoS One. 2023 Mar 16;18(3):e0282791. doi: 10.1371/journal.pone.0282791. eCollection 2023.
Reference Type
DERIVED
Mitro SD, Sundaram R, Chen Z, Peddada S, Buck Louis GM, Zhang C, Grewal J, Gleason JL, Sciscione AC, Grantz KL. Leiomyomata, neonatal anthropometry, and pregnancy outcomes in singleton pregnancies. Ann Epidemiol. 2023 Apr;80:43-52. doi: 10.1016/j.annepidem.2023.02.008. Epub 2023 Feb 21.
Reference Type
DERIVED
Tesfaye M, Wu J, Biedrzycki RJ, Grantz KL, Joseph P, Tekola-Ayele F. Prenatal social support in low-risk pregnancy shapes placental epigenome. BMC Med. 2023 Jan 8;21(1):12. doi: 10.1186/s12916-022-02701-w.
Reference Type
DERIVED
Ouidir M, Chatterjee S, Wu J, Tekola-Ayele F. Genomic study of maternal lipid traits in early pregnancy concurs with four known adult lipid loci. J Clin Lipidol. 2023 Jan-Feb;17(1):168-180. doi: 10.1016/j.jacl.2022.10.013. Epub 2022 Nov 17.
Reference Type
DERIVED
Liu X, Chen L, Fei Z, Zhao SK, Zhu Y, Xia T, Dai J, Rahman ML, Wu J, Weir NL, Tsai MY, Zhang C. Physical activity and individual plasma phospholipid SFAs in pregnancy: a longitudinal study in a multiracial/multiethnic cohort in the United States. Am J Clin Nutr. 2022 Dec 19;116(6):1729-1737. doi: 10.1093/ajcn/nqac250.
Reference Type
DERIVED
Mitro SD, Peddada S, Chen Z, Buck Louis GM, Gleason JL, Zhang C, Grantz KL. Natural history of fibroids in pregnancy: National Institute of Child Health and Human Development Fetal Growth Studies - Singletons cohort. Fertil Steril. 2022 Oct;118(4):656-665. doi: 10.1016/j.fertnstert.2022.06.028. Epub 2022 Aug 16.
Reference Type
DERIVED
Vafai Y, Yeung E, Roy A, He D, Li M, Hinkle SN, Grobman WA, Newman R, Gleason JL, Tekola-Ayele F, Zhang C, Grantz KL. The association between first-trimester omega-3 fatty acid supplementation and fetal growth trajectories. Am J Obstet Gynecol. 2023 Feb;228(2):224.e1-224.e16. doi: 10.1016/j.ajog.2022.08.007. Epub 2022 Aug 8.
Reference Type
DERIVED
Yisahak SF, Hinkle SN, Mumford SL, Gleason JL, Grantz KL, Zhang C, Grewal J. Periconceptional and First Trimester Ultraprocessed Food Intake and Maternal Cardiometabolic Outcomes. Diabetes Care. 2022 Sep 1;45(9):2028-2036. doi: 10.2337/dc21-2270.
Reference Type
DERIVED
Zhao SK, Yeung EH, Ouidir M, Hinkle SN, Grantz KL, Mitro SD, Wu J, Stevens DR, Chatterjee S, Tekola-Ayele F, Zhang C. Recreational physical activity before and during pregnancy and placental DNA methylation-an epigenome-wide association study. Am J Clin Nutr. 2022 Oct 6;116(4):1168-1183. doi: 10.1093/ajcn/nqac111.
Reference Type
DERIVED
Tekola-Ayele F, Zeng X, Chatterjee S, Ouidir M, Lesseur C, Hao K, Chen J, Tesfaye M, Marsit CJ, Workalemahu T, Wapner R. Placental multi-omics integration identifies candidate functional genes for birthweight. Nat Commun. 2022 May 2;13(1):2384. doi: 10.1038/s41467-022-30007-1.
Reference Type
DERIVED
Ghosal S, Grantz KL, Chen Z. Estimation of multiple ordered ROC curves using placement values. Stat Methods Med Res. 2022 Aug;31(8):1470-1483. doi: 10.1177/09622802221094940. Epub 2022 Apr 21.
Reference Type
DERIVED
Chatterjee S, Zeng X, Ouidir M, Tesfaye M, Zhang C, Tekola-Ayele F. Sex-specific placental gene expression signatures of small for gestational age at birth. Placenta. 2022 Apr;121:82-90. doi: 10.1016/j.placenta.2022.03.004. Epub 2022 Mar 12.
Reference Type
DERIVED
Ouidir M, Zeng X, Chatterjee S, Zhang C, Tekola-Ayele F. Ancestry-Matched and Cross-Ancestry Genetic Risk Scores of Type 2 Diabetes in Pregnant Women and Fetal Growth: A Study in an Ancestrally Diverse Cohort. Diabetes. 2022 Feb 1;71(2):340-349. doi: 10.2337/db21-0655.
Reference Type
DERIVED
Ouidir M, Chatterjee S, Mendola P, Zhang C, Grantz KL, Tekola-Ayele F. Placental Gene Co-expression Network for Maternal Plasma Lipids Revealed Enrichment of Inflammatory Response Pathways. Front Genet. 2021 Oct 21;12:681095. doi: 10.3389/fgene.2021.681095. eCollection 2021.
Reference Type
DERIVED
Li L, Zhu Y, Wu J, Hinkle SN, Tobias DK, Ma RCW, Weir NL, Tsai MY, Zhang C. Changes of Plasma Phospholipid Fatty Acids Profiles in Pregnancy in Relation to the Diagnosis and Treatment of Gestational Diabetes Mellitus. Clin Chem. 2021 Nov 26;67(12):1660-1675. doi: 10.1093/clinchem/hvab169.
Reference Type
DERIVED
Tesfaye M, Chatterjee S, Zeng X, Joseph P, Tekola-Ayele F. Impact of depression and stress on placental DNA methylation in ethnically diverse pregnant women. Epigenomics. 2021 Sep;13(18):1485-1496. doi: 10.2217/epi-2021-0192. Epub 2021 Sep 29.
Reference Type
DERIVED
McDonald SM, May LE, Hinkle SN, Grantz KL, Zhang C. Maternal Moderate-to-Vigorous Physical Activity before and during Pregnancy and Maternal Glucose Tolerance: Does Timing Matter? Med Sci Sports Exerc. 2021 Dec 1;53(12):2520-2527. doi: 10.1249/MSS.0000000000002730.
Reference Type
DERIVED
Li M, Grewal J, Hinkle SN, Yisahak SF, Grobman WA, Newman RB, Skupski DW, Chien EK, Wing DA, Grantz KL, Zhang C. Healthy dietary patterns and common pregnancy complications: a prospective and longitudinal study. Am J Clin Nutr. 2021 Sep 1;114(3):1229-1237. doi: 10.1093/ajcn/nqab145.
Reference Type
DERIVED
Grantz KL, Ortega-Villa AM, Pugh SJ, Bever A, Grobman W, Newman RB, Owen J, Wing DA, Albert PS. Combination of Fundal Height and Ultrasound to Predict Small for Gestational Age at Birth. Am J Perinatol. 2023 Jan;40(2):155-162. doi: 10.1055/s-0041-1728837. Epub 2021 May 3.
Reference Type
DERIVED
Tekola-Ayele F, Ouidir M, Shrestha D, Workalemahu T, Rahman ML, Mendola P, Grantz KL, Hinkle SN, Wu J, Zhang C. Admixture mapping identifies African and Amerindigenous local ancestry loci associated with fetal growth. Hum Genet. 2021 Jul;140(7):985-997. doi: 10.1007/s00439-021-02265-4. Epub 2021 Feb 15.
Reference Type
DERIVED
Vafai Y, Yeung EH, Sundaram R, Smarr MM, Gerlanc N, Grobman WA, Skupski D, Chien EK, Hinkle SN, Newman RB, Wing DA, Ranzini AC, Sciscione A, Grewal J, Zhang C, Grantz KL. Racial/Ethnic Differences in Prenatal Supplement and Medication Use in Low-Risk Pregnant Women. Am J Perinatol. 2022 Apr;39(6):623-632. doi: 10.1055/s-0040-1717097. Epub 2020 Oct 8.
Reference Type
DERIVED
Ouidir M, Zeng X, Workalemahu T, Shrestha D, Grantz KL, Mendola P, Zhang C, Tekola-Ayele F. Early pregnancy dyslipidemia is associated with placental DNA methylation at loci relevant for cardiometabolic diseases. Epigenomics. 2020 Jun;12(11):921-934. doi: 10.2217/epi-2019-0293. Epub 2020 Jul 17.
Reference Type
DERIVED
Tekola-Ayele F, Zeng X, Ouidir M, Workalemahu T, Zhang C, Delahaye F, Wapner R. DNA methylation loci in placenta associated with birthweight and expression of genes relevant for early development and adult diseases. Clin Epigenetics. 2020 Jun 3;12(1):78. doi: 10.1186/s13148-020-00873-x.
Reference Type
DERIVED
Tekola-Ayele F, Zhang C, Wu J, Grantz KL, Rahman ML, Shrestha D, Ouidir M, Workalemahu T, Tsai MY. Trans-ethnic meta-analysis of genome-wide association studies identifies maternal ITPR1 as a novel locus influencing fetal growth during sensitive periods in pregnancy. PLoS Genet. 2020 May 14;16(5):e1008747. doi: 10.1371/journal.pgen.1008747. eCollection 2020 May.
Reference Type
DERIVED
Li M, Hinkle SN, Grantz KL, Kim S, Grewal J, Grobman WA, Skupski DW, Newman RB, Chien EK, Sciscione A, Zork N, Wing DA, Nageotte M, Tekola-Ayele F, Louis GMB, Albert PS, Zhang C. Glycaemic status during pregnancy and longitudinal measures of fetal growth in a multi-racial US population: a prospective cohort study. Lancet Diabetes Endocrinol. 2020 Apr;8(4):292-300. doi: 10.1016/S2213-8587(20)30024-3. Epub 2020 Mar 2.
Reference Type
DERIVED
Workalemahu T, Ouidir M, Shrestha D, Wu J, Grantz KL, Tekola-Ayele F. Differential DNA Methylation in Placenta Associated With Maternal Blood Pressure During Pregnancy. Hypertension. 2020 Apr;75(4):1117-1124. doi: 10.1161/HYPERTENSIONAHA.119.14509. Epub 2020 Feb 10.
Reference Type
DERIVED
Smarr MM, Bible J, Gerlanc N, Buck Louis GM, Bever A, Grantz KL. Comparison of fetal growth by maternal prenatal acetaminophen use. Pediatr Res. 2019 Aug;86(2):261-268. doi: 10.1038/s41390-019-0379-7. Epub 2019 Mar 25.
Reference Type
DERIVED
Rawal S, Tsai MY, Hinkle SN, Zhu Y, Bao W, Lin Y, Panuganti P, Albert PS, Ma RCW, Zhang C. A Longitudinal Study of Thyroid Markers Across Pregnancy and the Risk of Gestational Diabetes. J Clin Endocrinol Metab. 2018 Jul 1;103(7):2447-2456. doi: 10.1210/jc.2017-02442.
Reference Type
DERIVED
Zhu Y, Tsai MY, Sun Q, Hinkle SN, Rawal S, Mendola P, Ferrara A, Albert PS, Zhang C. A prospective and longitudinal study of plasma phospholipid saturated fatty acid profile in relation to cardiometabolic biomarkers and the risk of gestational diabetes. Am J Clin Nutr. 2018 Jun 1;107(6):1017-1026. doi: 10.1093/ajcn/nqy051.
Reference Type
DERIVED
Bever AM, Pugh SJ, Kim S, Newman RB, Grobman WA, Chien EK, Wing DA, Li H, Albert PS, Grantz KL. Fetal Growth Patterns in Pregnancies With First-Trimester Bleeding. Obstet Gynecol. 2018 Jun;131(6):1021-1030. doi: 10.1097/AOG.0000000000002616.
Reference Type
DERIVED
Grantz KL, Hediger ML, Liu D, Buck Louis GM. Fetal growth standards: the NICHD fetal growth study approach in context with INTERGROWTH-21st and the World Health Organization Multicentre Growth Reference Study. Am J Obstet Gynecol. 2018 Feb;218(2S):S641-S655.e28. doi: 10.1016/j.ajog.2017.11.593. Epub 2017 Dec 22.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-CH-N152
Identifier Type: -
Identifier Source: secondary_id
999909152
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
NCT02273297
RECRUITING
Maternal Obesity and Small for Gestational Age Infants
NCT00371657
COMPLETED
Prenatal Genetic Diagnosis by Genomic Sequencing
NCT03936101
COMPLETED
Antenatal Detection by Array CGH Genomic Rearrangements Unbalanced Front Uninsulated Thick Neck or a Combination of Two Signs of Ultrasound Calling Normal Karyotype
NCT03239002
COMPLETED
Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Retardation: A Longtitudinal Study
NCT00340899
COMPLETED
Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies
NCT03398629
RECRUITING
A First Trimester Prediction Model for Large for Gestational Age Infants: a Preliminary Study
NCT04838431
TERMINATED
Effects of Serial Plotting on Fundal Height Charts on Identification and Outcomes of Small for Gestational Age Infants
NCT02964793
UNKNOWN
NA
The Use of Early Pregnancy HbA1c in Predicting Excessive Fetal Growth in Women at Risk of Glucose Intolerance
NCT04858386
TERMINATED
Impact of Ultrasound Fetal Weight Estimation on Obstetrical Management and Maternal and Neonatal Outcomes
NCT05530616
COMPLETED
Antenatal Detection of Fetal Growth Restriction and Stillbirths Rate.
NCT01995968
UNKNOWN
Antenatal Testing in Obese Woman, is it Really Necessary?
NCT02821988
UNKNOWN
NA
Regulation Of Maternal Fuel Supply And Neonatal Adiposity
NCT00826904
COMPLETED
Investigating the Relationship Between Triglycerides and Fetal Overgrowth in Gestational Diabetes
NCT06067685
TERMINATED
Fetal Growth Restriction a Case Control Study
NCT07025031
NOT_YET_RECRUITING
The Role of Cytokines in Apparently Normal Pregnancies
NCT01098214
WITHDRAWN
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
NCT05952583
RECRUITING
Early Pregnancy Evaluation by Three-Dimensional Ultrasound
NCT00342290
TERMINATED
Doppler at the Diagnosis in Predicting Perinatal Outcomes in Early and Late-onset Fetal Growth Restriction
NCT05696223
COMPLETED
Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR)
NCT06096805
RECRUITING
Point of Care Ultrasound Screening for Abnormal Fetal Growth During Routine Antenatal Visits
NCT03715036
COMPLETED
NA
Antenatal Corticosteroid Therapy: Which Impact on Birth Parameters?
NCT05640596
COMPLETED
Fetal 3D Study (Fetal Body Composition and Volumes Study)
NCT03266198
COMPLETED
Biophysical Profile in Preterm Pregnancies
NCT02561364
COMPLETED